F. Moazed, C.M. Hendrickson, A. Jauregui, K. Vessel, T. Deiss, S. Ke, J. Abbott, H. Zhuo, A.D. Gomez, P. Sinha, K.N. Kangelaris, M.A. Matthay, K. Liu, C.S. Calfee
Tsoh J, Apollonio DE, Hall S, Vijayaraghvan M, Ramo DE, Ling P, Lempert LL, Glantz SA. FDA’s Nicotine Steering Committee should develop policies, regulations, and procedures that promote cessation and increase the use of proven therapies. US FDA Public Comment, Docket FDA-2018-N-0128.
Apollonio DE, Glantz SA, Hall S, Lempert LL, St.Helen G, Tsoh J. The FDA should not adopt the nicotine “harm reduction” paradigm because doing so is likely to increase the amount of smoking-caused disease and death. US FDA Public Comment, Docket FDA-2017-N-6529.